Technical Analysis for SYRE - Spyre Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 24.55 | 4.42% | 1.04 |
SYRE closed up 4.42 percent on Monday, July 1, 2024, on 1.19 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Flat | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 4.42% | |
| Volume Surge | Other | 4.42% | |
| Wide Bands | Range Expansion | 4.42% | |
| Oversold Stochastic | Weakness | 4.42% | |
| Wide Bands | Range Expansion | 8.10% | |
| Oversold Stochastic | Weakness | 8.10% | |
| Wide Bands | Range Expansion | 4.96% |
| Alert | Time |
|---|---|
| Rose Above 10 DMA | about 5 hours ago |
| 10 DMA Resistance | about 5 hours ago |
| Up 3% | about 5 hours ago |
| Possible NR7 | about 6 hours ago |
| 60 Minute Opening Range Breakout | about 6 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/09/2024
Spyre Therapeutics is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Immunology Autoimmune Disease Antibodies Monoclonal Antibody Antibody Inflammatory Bowel Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Immunology Autoimmune Disease Antibodies Monoclonal Antibody Antibody Inflammatory Bowel Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 47.97 |
| 52 Week Low | 8.43 |
| Average Volume | 620,818 |
| 200-Day Moving Average | 24.65 |
| 50-Day Moving Average | 32.75 |
| 20-Day Moving Average | 29.60 |
| 10-Day Moving Average | 24.24 |
| Average True Range | 2.56 |
| RSI (14) | 35.90 |
| ADX | 28.63 |
| +DI | 13.40 |
| -DI | 25.92 |
| Chandelier Exit (Long, 3 ATRs) | 31.23 |
| Chandelier Exit (Short, 3 ATRs) | 29.86 |
| Upper Bollinger Bands | 40.79 |
| Lower Bollinger Band | 18.42 |
| Percent B (%b) | 0.27 |
| BandWidth | 75.57 |
| MACD Line | -3.15 |
| MACD Signal Line | -2.59 |
| MACD Histogram | -0.5522 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 27.42 | ||||
| Resistance 3 (R3) | 27.22 | 26.07 | 26.94 | ||
| Resistance 2 (R2) | 26.07 | 25.34 | 26.17 | 26.78 | |
| Resistance 1 (R1) | 25.31 | 24.88 | 25.69 | 25.51 | 26.62 |
| Pivot Point | 24.15 | 24.15 | 24.34 | 24.25 | 24.15 |
| Support 1 (S1) | 23.39 | 23.42 | 23.77 | 23.59 | 22.48 |
| Support 2 (S2) | 22.24 | 22.97 | 22.34 | 22.32 | |
| Support 3 (S3) | 21.48 | 22.24 | 22.16 | ||
| Support 4 (S4) | 21.68 |
